Showing results (261-270 of 296) with videos related to

Sort By:
Pageof 30
Blood|June 22, 2001
Prognostic factors and response to fludarabine therapy in patients with Waldenström macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003)M V Dhodapkar, J L Jacobson, M A Gertz, et al.
Bone Marrow Transplantation|March 14, 2000
Melphalan plus total body irradiation (MEL-TBI) or cyclophosphamide (MEL-CY) as a conditioning regimen with second autotransplant in responding patients with myeloma is inferior compared to historical controls receiving tandem transplants with melphalan aloneK R Desikan, G Tricot, M Dhodapkar, et al.
Bone Marrow Transplantation|April 1, 1990
High dose cyclophosphamide, BCNU and VP-16 with autologous blood stem cell support for refractory multiple myelomaG J Ventura, B Barlogie, J P Hester, et al.
Blood|December 24, 1998
Age is not a prognostic variable with autotransplants for multiple myelomaD S Siegel, K R Desikan, J Mehta, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|April 11, 2002
Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complicationsM Zangari, F Saghafifar, E Anaissie, et al.
Bone Marrow Transplantation|December 12, 2002
Transplantation as salvage therapy for high-risk patients with myeloma in relapseC-K Lee, B Barlogie, M Zangari, et al.
Leukemia|November 4, 2015
Clinical value of molecular subtyping multiple myeloma using gene expression profilingN Weinhold, C J Heuck, A Rosenthal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 29, 1998
Comparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myelomaK R Desikan, B Barlogie, S Jagannath, et al.
Blood|February 15, 1997
Thymidine kinase (TK) gene-transduced human lymphocytes can be highly purified, remain fully functional, and are killed efficiently with ganciclovirN C Munshi, R Govindarajan, R Drake, et al.
Bone Marrow Transplantation|July 16, 2013
Modified high-dose melphalan and autologous SCT for AL amyloidosis or high-risk myeloma: analysis of SWOG trial S0115V Sanchorawala, A Hoering, D C Seldin, et al.
Pageof 30